Polycystic Ovary Syndrome Medical Services in China

Polycystic Ovary Syndrome (PCOS) is a common, complex endocrine-metabolic disorder affecting individuals of reproductive age. It is characterized by chronic anovulation, hyperandrogenism (clinical or biochemical), and polycystic ovarian morphology on ultrasound—though diagnosis requires at least two of these three criteria per the Rotterdam criteria, after excluding other causes of hyperandrogenism and anovulation. PCOS is not merely a gynecological condition but a systemic disorder with profound implications for metabolic, cardiovascular, and psychological health. Its pathogenesis remains incompletely understood but involves a combination of genetic predisposition, insulin resistance, compensatory hyperinsulinemia, and neuroendocrine dysregulation—particularly exaggerated luteinizing hormone (LH) pulsatility and altered gonadotropin-releasing hormone (GnRH) secretion. Insulin resistance drives ovarian theca cell androgen overproduction and impairs follicular maturation, while adipose tissue inflammation and dysbiosis may further amplify hormonal and metabolic dysfunction. Epidemiologically, PCOS affects approximately 6–12% of women globally, with prevalence varying by diagnostic criteria and population—studies in China report rates of 5.6–8.7% among reproductive-age women. Risk factors include family history (first-degree relatives with PCOS or type 2 diabetes), obesity (especially central adiposity), sedentary lifestyle, prenatal androgen exposure, and early menarche. Importantly, PCOS is strongly associated with long-term comorbidities: up to 40% develop prediabetes or type 2 diabetes by age 40; 30–50% have metabolic syndrome; and cardiovascular risk markers—including hypertension, dyslipidemia, and endothelial dysfunction—are significantly elevated. Beyond physiology, PCOS substantially impacts quality of life: menstrual irregularity, hirsutism, acne, alopecia, and infertility contribute to body image distress, anxiety, depression (prevalence 25–40%), and reduced sexual well-being. Social stigma around appearance and fertility challenges often leads to delayed help-seeking and treatment nonadherence. Early diagnosis and individualized, multidisciplinary management—spanning endocrinology, gynecology, nutrition, and mental health—are critical to mitigate both immediate symptoms and lifelong morbidity.

Polycystic Ovary Syndrome (PCOS) is a heterogeneous, multifactorial endocrine-metabolic disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology—diagnosed in the absence of other specific etiologies such as nonclassical congenital adrenal hyperplasia, Cushing’s syndrome, or hyperprolactinemia. The precise pathogenesis remains incompletely elucidated, but current evidence supports a complex interplay among genetic susceptibility, intrinsic ovarian abnormalities, hypothalamic-pituitary-ovarian axis dysregulation, insulin resistance, chronic low-grade inflammation, and environmental influences.

Common causes are not attributable to a single etiologic agent but rather reflect convergent pathophysiological pathways. Insulin resistance—present in approximately 65–80% of individuals with PCOS, independent of BMI—is a central driver. Hyperinsulinemia stimulates ovarian theca cell androgen synthesis and suppresses hepatic sex hormone-binding globulin (SHBG) production, thereby increasing bioavailable testosterone. Concurrently, gonadotropin dysregulation manifests as elevated luteinizing hormone (LH) pulse amplitude and frequency relative to follicle-stimulating hormone (FSH), promoting premature follicular arrest and anovulation. Intrinsic ovarian defects—including aberrant granulosa cell aromatase activity, altered follicular fluid composition, and dysregulated anti-Müllerian hormone (AMH) signaling—further impair folliculogenesis and contribute to cystic follicle accumulation.

Triggers often precipitate or exacerbate clinical manifestations in genetically predisposed individuals. Puberty represents a key developmental window during which hormonal surges may unmask latent PCOS traits. Significant weight gain—particularly central adiposity—amplifies insulin resistance and adipokine dysregulation (e.g., elevated leptin, reduced adiponectin), intensifying hyperandrogenism and anovulation. Chronic psychosocial stress may augment hypothalamic corticotropin-releasing hormone (CRH) output, indirectly stimulating adrenal androgen production and disrupting GnRH pulsatility. Sleep disturbances—including obstructive sleep apnea and circadian misalignment—impair glucose metabolism and amplify sympathetic tone, worsening metabolic and reproductive phenotypes.

Established risk factors include obesity (especially visceral adiposity), sedentary lifestyle, and advancing age during adolescence and early adulthood, when diagnostic criteria become more reliably identifiable. A family history of PCOS, type 2 diabetes mellitus (T2DM), or early-onset cardiovascular disease significantly increases risk. Maternal exposure to gestational diabetes or excess androgens *in utero* may induce fetal programming alterations in hypothalamic development and ovarian steroidogenesis, conferring lifelong susceptibility. Early menarche (<11 years) and rapid weight gain during childhood are also associated with increased PCOS incidence.

Genetic factors underpin PCOS heritability, estimated at 70%. Genome-wide association studies (GWAS) have identified over 20 robust susceptibility loci implicating genes involved in gonadotropin action (*FSHR*, *LHCGR*), insulin signaling (*INSR*, *IRS1*, *PPARG*), and androgen biosynthesis and metabolism (*CYP11A1*, *CYP17A1*, *SHBG*, *DENND1A*). Epigenetic modifications—including DNA methylation changes in promoters of *INSR* and *CYP19A1*—may mediate gene-environment interactions and explain phenotypic variability across affected individuals. Familial clustering suggests autosomal dominant inheritance with variable penetrance and strong gene–gene and gene–environment interactions.

Environmental factors modulate expression and severity. Endocrine-disrupting chemicals (EDCs)—such as bisphenol A (BPA), phthalates, and persistent organic pollutants—interfere with nuclear receptor signaling (e.g., estrogen and androgen receptors), alter steroidogenic enzyme activity, and promote adipose tissue inflammation and insulin resistance. Dietary patterns high in refined carbohydrates, saturated fats, and advanced glycation end-products (AGEs) exacerbate oxidative stress and mitochondrial dysfunction in ovarian and metabolic tissues. Urban living, chronic noise exposure, and air pollution (e.g., PM2.5) correlate with systemic inflammation and dysregulated cortisol metabolism, potentially contributing to neuroendocrine perturbations. Socioeconomic determinants—including food insecurity, limited access to preventive care, and occupational stressors—also influence disease onset, progression, and long-term comorbidity burden, particularly in underserved populations.

Polycystic Ovary Syndrome (PCOS) is a heterogeneous, multifactorial endocrine-metabolic disorder affecting approximately 6–12% of reproductive-aged individuals worldwide. It is characterized by ovarian dysfunction, hyperandrogenism, and polycystic ovarian morphology on ultrasound—though not all features are required for diagnosis. As an endocrinologic condition, PCOS involves dysregulation of the hypothalamic-pituitary-ovarian (HPO) axis, insulin resistance, chronic low-grade inflammation, and aberrant adipokine signaling.

Early symptoms typically emerge during adolescence or early adulthood, often around menarche or within the first few years post-menarche. Menstrual irregularity is frequently the earliest and most common presenting feature: oligomenorrhea (cycles >35 days), amenorrhea (>90 days without menses), or prolonged, unpredictable bleeding due to chronic anovulation. Acne—particularly inflammatory, persistent, or resistant to conventional therapy—often appears in the mid-to-late teens and may involve the lower face, jawline, and upper back. Hirsutism, defined as excessive terminal hair growth in androgen-sensitive areas (e.g., upper lip, chin, chest, abdomen, inner thighs), usually develops insidiously over months to years and reflects peripheral androgen excess. Early-onset alopecia—typically frontal-temporal thinning consistent with female-pattern hair loss—is less common initially but may signal progressive hyperandrogenism. Subtle signs include acanthosis nigricans (velvety, hyperpigmented skin patches at the nape of the neck, axillae, or groin), which strongly correlates with insulin resistance and often precedes overt metabolic abnormalities.

Typical symptoms reflect the core pathophysiologic triad. Chronic anovulation manifests as infertility, recurrent pregnancy loss, or subfertility—often prompting clinical evaluation. Hyperandrogenism presents clinically as hirsutism (Ferriman-Gallwey score ≥4–6 depending on ethnicity), moderate-to-severe acne, and androgenic alopecia. Polycystic ovarian morphology (PCOM), observed via transvaginal ultrasound, is defined as the presence of ≥20 follicles per ovary (2–9 mm in diameter) and/or increased ovarian volume (>10 mL), though PCOM alone is neither diagnostic nor specific. Weight gain—especially central adiposity—and difficulty losing weight are highly prevalent; up to 80% of individuals with PCOS are overweight or obese, and even lean phenotypes exhibit visceral adiposity and insulin resistance. Fatigue, sleep disturbances—including obstructive sleep apnea (OSA)—and mood lability are frequently underrecognized yet integral components.

Accompanying symptoms underscore the systemic nature of PCOS. Metabolic manifestations include acanthosis nigricans, skin tags (fibroepithelial polyps), and impaired glucose tolerance—present in ~30–40% of affected individuals by age 30. Dyslipidemia (elevated triglycerides, low HDL-C, small dense LDL particles) is common. Reproductive tract anomalies such as endometrial hyperplasia may arise from unopposed estrogen exposure secondary to chronic anovulation, occasionally presenting as intermenstrual spotting or postcoital bleeding. Gastrointestinal complaints—including bloating, constipation, and irritable bowel syndrome-like symptoms—are reported more frequently than in controls, potentially linked to gut microbiota dysbiosis and low-grade inflammation. Psychological comorbidities are highly prevalent: anxiety disorders affect ~34–57%, depression ~25–45%, and disordered eating behaviors (e.g., binge-eating disorder) occur in ~15–30%. Reduced quality of life, body image distress, and sexual dysfunction are consistently documented across diverse populations.

Complications evolve over time and significantly impact long-term morbidity and mortality. Endometrial carcinoma risk is 2–6 times higher due to chronic unopposed estrogen stimulation and resultant endometrial hyperplasia. Type 2 diabetes mellitus develops in ~30–40% by age 40, with earlier onset and greater severity than in matched controls. Cardiovascular disease risk is elevated: hypertension prevalence is 2–3-fold higher; subclinical atherosclerosis (e.g., increased carotid intima-media thickness) is detectable in young adults; and coronary artery calcification rates rise prematurely. Obstructive sleep apnea affects ~50–70% of obese individuals with PCOS and contributes to insulin resistance and cardiovascular strain. Nonalcoholic fatty liver disease (NAFLD) occurs in ~30–55%, with increased risk of fibrosis progression. Pregnancy complications include gestational diabetes (3–4× increased risk), preeclampsia (2–3×), preterm birth, and miscarriage (1.5–2×). Longitudinal data also suggest modestly increased risks of breast and ovarian cancers, though evidence remains inconclusive.

Diagnosis relies on the Rotterdam Criteria (2003), requiring ≥2 of the following after exclusion of other etiologies: (1) oligo- and/or anovulation; (2) clinical and/or biochemical signs of hyperandrogenism; (3) polycystic ovaries on ultrasound. First-line biochemical testing includes serum total testosterone (preferably morning, non-fasting), sex hormone-binding globulin (SHBG), and calculated free androgen index (FAI); dehydroepiandrosterone sulfate (DHEA-S) and androstenedione help exclude non-ovarian sources. Fasting glucose, HbA1c, and oral glucose tolerance test (OGTT) assess glycemic status; lipid profile, liver enzymes, and blood pressure screen for metabolic comorbidities. Pelvic ultrasound—ideally transvaginal with standardized technique—is used to evaluate ovarian morphology and rule out structural pathology. Anti-Müllerian hormone (AMH) levels >4.7 ng/mL show high sensitivity/specificity for PCOS but remain adjunctive pending standardization.

Differential diagnosis is critical to avoid misattribution. Nonclassical congenital adrenal hyperplasia (NCAH) mimics PCOS with hyperandrogenism and oligomenorrhea but demonstrates elevated 17-hydroxyprogesterone (especially after ACTH stimulation). Hyperprolactinemia causes anovulation and galactorrhea but lacks hyperandrogenic features; prolactin measurement is mandatory. Thyroid dysfunction—particularly hypothyroidism—can cause menstrual disturbance and weight gain; TSH and free T4 must be assessed. Premature ovarian insufficiency (POI) presents with amenorrhea and elevated FSH (>25 IU/L), contrasting with normal or mildly elevated FSH in PCOS. Cushing syndrome exhibits central obesity, striae, hypertension, and cortisol excess (dexamethasone suppression test, late-night salivary cortisol). Androgen-secreting tumors (e.g., ovarian or adrenal) cause rapid-onset virilization (clitoromegaly, deepening voice, temporal balding) and markedly elevated testosterone (>150 ng/dL) or DHEA-S (>700 µg/dL). Finally, functional hypothalamic amenorrhea—associated with stress, low energy availability, or excessive exercise—features low gonadotropins and estradiol, distinguishing it from the normo- or hypergonadotropic state of PCOS. Comprehensive evaluation ensures accurate diagnosis, appropriate risk stratification, and individualized, multidisciplinary management.

Polycystic Ovary Syndrome (PCOS) is a heterogeneous endocrine-metabolic disorder affecting approximately 6–12% of women of reproductive age worldwide. Characterized by chronic anovulation, hyperandrogenism (clinical or biochemical), and polycystic ovarian morphology on ultrasound—diagnosed using the Rotterdam criteria—PCOS is associated with insulin resistance, obesity, dyslipidemia, increased risk of type 2 diabetes mellitus (T2DM), cardiovascular disease, endometrial hyperplasia, and infertility. Management in the Department of Endocrinology emphasizes individualized, multidisciplinary, and long-term strategies targeting both reproductive and metabolic manifestations.

Conservative treatment forms the cornerstone of PCOS management, particularly for overweight or obese patients (BMI ≥25 kg/m²). Lifestyle modification—including structured dietary intervention, regular physical activity, and behavioral support—is evidence-based first-line therapy. A hypocaloric, low-glycemic-index diet emphasizing whole grains, lean protein, fiber-rich vegetables, and healthy fats improves insulin sensitivity and reduces androgen levels. Supervised aerobic and resistance exercise for ≥150 minutes per week has demonstrated significant reductions in body weight (5–10%), waist circumference, fasting insulin, and free testosterone, while restoring ovulatory function in up to 40% of previously anovulatory women. Cognitive-behavioral therapy (CBT) and digital health platforms are increasingly integrated into Chinese outpatient programs to enhance adherence, address body image concerns, and mitigate anxiety/depression comorbidities prevalent in PCOS.

Pharmacotherapy is initiated based on symptom priority: menstrual irregularity, hirsutism/acne, infertility, or metabolic risk. Combined oral contraceptives (COCs)—containing ethinyl estradiol and a low-androgenic progestin (e.g., drospirenone or norgestimate)—are first-line for cycle regulation, endometrial protection, and androgen suppression. Metformin remains widely used off-label in insulin-resistant PCOS, especially in adolescents and preconception counseling; it improves ovulation rates, reduces hyperinsulinemia, and may lower miscarriage risk. In China, metformin is often prescribed at 500–1500 mg/day, titrated gradually to minimize gastrointestinal side effects. For hyperandrogenism refractory to COCs, spironolactone (50–200 mg/day) is commonly employed as an antiandrogen, though contraception must be strictly enforced due to teratogenic risk. Clomiphene citrate remains the initial ovulation induction agent for infertility; however, letrozole—a selective aromatase inhibitor—is now preferred in many Chinese fertility centers due to superior live birth rates and lower multiple pregnancy risk. GLP-1 receptor agonists (e.g., semaglutide, approved in China for obesity/T2DM) are emerging as adjunctive agents in PCOS with obesity and prediabetes, demonstrating robust weight loss, improved insulin sensitivity, and restoration of menstrual cyclicity in early-phase trials.

Surgical treatment plays a limited but defined role. Laparoscopic ovarian drilling (LOD) is reserved for clomiphene- or letrozole-resistant anovulatory infertility after thorough evaluation of tubal patency and male factor. Performed under general anesthesia, LOD involves diathermy or laser ablation of 3–5 ovarian wedge sites, reducing ovarian stromal volume and local androgen production. It restores spontaneous ovulation in ~70% of responders within 3–6 months, with cumulative pregnancy rates comparable to gonadotropin therapy but without the risks of ovarian hyperstimulation syndrome (OHSS) or multiple gestation. However, LOD carries potential complications including adhesion formation, ovarian failure (rare), and technical variability. In China, LOD is performed in tertiary endocrinology-reproductive centers with standardized protocols and intraoperative laparoscopic ultrasound guidance to optimize precision and safety. It is not indicated for metabolic management or hirsutism alone.

Treatment advantages in China include rapid integration of national clinical guidelines (e.g., the 2023 Chinese Society of Endocrinology PCOS Consensus), widespread access to tiered healthcare delivery, and advanced digital infrastructure supporting longitudinal monitoring. Many provincial hospitals utilize AI-powered platforms for real-time tracking of anthropometrics, menstrual logs, and home glucose monitoring, enabling proactive intervention. Traditional Chinese Medicine (TCM) is frequently incorporated as complementary therapy—e.g., acupuncture for menstrual regulation or herbal formulas like Gui Zhi Fu Ling Wan for blood stasis patterns—under dual-endocrinologist/TCM physician supervision, with growing evidence for synergistic effects on insulin sensitivity and inflammation. Furthermore, China’s centralized pharmaceutical procurement system ensures affordability of essential agents (metformin, COCs, spironolactone), and national insurance coverage extends to fertility-related diagnostics and letrozole for ovulation induction.

Recovery and long-term follow-up are integral to sustainable outcomes. Patients are advised to maintain weight stability post-intervention, with quarterly endocrinology visits during active treatment and annual comprehensive assessments thereafter—including fasting glucose, HbA1c, lipid profile, liver enzymes, blood pressure, and pelvic ultrasound if clinically indicated. Endometrial surveillance via transvaginal ultrasound or saline infusion sonography is recommended for women with prolonged amenorrhea (>6 months) or abnormal uterine bleeding. Psychological well-being must be routinely assessed; referral to clinical psychology services is standard in major Chinese centers. Breastfeeding is encouraged postpartum, as it confers metabolic benefits and may delay PCOS symptom recurrence. Adolescents require specialized transition care from pediatric to adult endocrinology services, with emphasis on education about self-management, contraception, and future fertility planning. Finally, all women with PCOS should receive cardiovascular risk counseling, including smoking cessation, sodium restriction, and aspirin consideration only in high-risk subgroups per ASCVD risk calculators validated in Asian populations. With consistent, patient-centered care, most individuals achieve symptom control, metabolic stabilization, and reproductive autonomy—underscoring PCOS not as a static diagnosis but a lifelong, modifiable endocrine trajectory.